

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Benjamin W. McDonough, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than April 6, 2026.

A. Federal Reserve Bank of Minneapolis (Mark Nagle, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291. Comments can also be sent electronically to MA@mpls.frb.org:

1. *Vicki Clark, Lake Placid, Florida; Ann Carda, Saint Louis Park, Minnesota; and Thomas Clark, Sioux Center, Iowa*; to join the Clark Family Control Group, a group acting in concert, to retain voting shares of Chandler Bancshares, Inc., Chandler, Minnesota, through joint ownership of the shares with Lonnie Clark, Chandler, Minnesota, and thereby indirectly retain voting shares of State Bank of Chandler, Chandler, Minnesota. Lonnie Clark is a member of the Clark Family Control Group and was previously permitted by the Federal Reserve System to acquire voting shares of Chandler Bancshares, Inc., in his individual capacity.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2026-05531 Filed 3-19-26; 8:45 am]

BILLING CODE P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Benjamin W. McDonough, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than April 20, 2026.

A. Federal Reserve Bank of New York (Keith Goodwin, Head of Bank Applications) 33 Liberty Street, New York, New York 10045-0001. Comments can also be sent electronically to Comments.applications@ny.frb.org:

1. *The Bank of Nova Scotia, Toronto, Canada*; to acquire additional voting shares, up to 19.99 percent, of KeyCorp, and thereby indirectly acquire voting shares of KeyBank National Association, both of Cleveland, Ohio.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2026-05530 Filed 3-19-26; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Assistance Listing Numbers: 93.612, 93.340]

Notice for Public Comment on Administration for Native Americans' Program Policies and Procedures

AGENCY: Administration for Native Americans (ANA), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).

ACTION: Notice for public comment.

SUMMARY: ANA is required to provide members of the public an opportunity to comment on proposed changes in interpretive rules and general statements of policy and to give notice of the proposed changes no less than 30 days before such changes become effective. ANA herein describes proposed interpretive rules and general statements of policy that relate to ANA's Notices of Funding Opportunities (NOFOs) in fiscal year (FY) 2026.

DATES: Comments are due by April 20, 2026. If ANA does not receive substantial comments within the 30-day comment period, ANA will proceed with the proposed changes in the respective published NOFOs. The NOFOs will serve as the final notice of these proposed changes.

ADDRESSES: Comments may be submitted to: Carmelia Strickland, Administration for Native Americans, 330 C Street SW, Washington, DC 20201 or via email to: anacomments@acf.hhs.gov.

FOR FURTHER INFORMATION CONTACT: Carmelia Strickland, Administration for Native Americans, 330 C Street SW, Washington, DC 20201 or via email to: anacomments@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: Section 814 of the Native American Programs Act of 1974 (NAPA), as amended (42 U.S.C. 2992b-1), incorporates provisions of the Administrative Procedure Act that require ANA to provide notice of its proposed interpretive rules and statements of policy and to seek public comment on such proposals. This notice serves to fulfill the statutory notice and public comment requirement. The proposed interpretive rules, statements of policy, and rules of ANA practice and procedure reflected in new text will appear in the FY 2026 NOFOs for Economic Advancement Grants for Local Empowerment (EAGLE), AI³

Action Institute—Artificial Intelligence for American Indians (AI³ Action Institute), and the National Center for Native Training and Technical Assistance (NCNTTA). There will be no significant changes to the following ANA NOFOs: Environmental Regulatory Enhancement; Native American Language Preservation and Maintenance—Esther Martinez Immersion; and Native American Language Preservation and Maintenance.

Interpretive rules, statements of policy, procedures, and practice. The proposals in this subsection reflect ANA's proposed updates in rules, policy, or procedure that will take effect in the FY 2026 EAGLE NOFO, AI³ Action Institute NOFO, and NCNTTA NOFO

1. Programmatic Update

A. The Social and Economic Development Strategies (SEDS) and SEDS-Alaska (SEDS-AK) NOFOs will be replaced by EAGLE and the AI³ Action Institute. This will not impact any existing SEDS or SEDS-AK awards.

The EAGLE NOFO will reflect the Administration's pro-growth agenda, strengthen both socioeconomic and cultural success, and bridge ANA's past with new approaches and opportunities to empower communities and underwrite self-determination. EAGLE will place a greater emphasis on economic development, a priority that was identified at numerous conferences ANA attended in 2025 and reinforced during ANA's 2025 Tribal Economic Development Consultation. EAGLE will embrace thoughtful human capital development, strategic infrastructure reform, family stability efforts, and innovative business creation. EAGLE will include greenhouses to promote healthy diets. It will focus on welding skills to boost employability and reduce high unemployment. It will help native communities adopt microgrids to boost energy reliability and help underpin socioeconomic development. It will embrace tribal elder mentorship of youth to promote success in education, strengthen the future workforce, and boost cultural rootedness. Moreover, EAGLE will further self-determination by accepting project proposals conceptualized by native communities. The EAGLE NOFO will be the intersection of native communities' needs and priorities, ANA's commitment to self-determination, and Administration priorities. EAGLE is a strategic empowerment framework with multiple project areas (PAs), and applicants will be allowed to apply to one or more PAs.

The AI³ Action Institute will empower native communities by facilitating the adoption of cutting-edge technologies. The recipient of this award will support tribes by reducing the AI learning curve; identifying the best technologies and facilitating deployment; optimize benefits of AI; and acting as a knowledge manager to accumulate lessons learned.

B. ANA will consolidate four existing Training and Technical Assistance (TTA) contracts into a single cooperative agreement, which will enable integration of services, strengthen the quality and impact of TTA delivered, by creating a unified, more agile framework for delivering TTA services. This change will focus TTA support to strengthen recipient capacity, performance, and sustainability. For ANA, the cooperative agreement will enhance operational integration, reduce administrative burden, provide cost savings, and more efficiently respond to the Administration priorities. It will also increase flexibility to respond to the needs of ANA's community of grant recipients. This structure will increase oversight, improve quality and outcomes, and support a more agile and sustainable operational framework that is not possible under a traditional contract.

Eligibility and Funding Information

A. ANA intends to fully fund FY 2026 EAGLE awards for 3 years, and the new NOFO will be comprised of multiple PAs included below.

- Seventh-Generation Greenhouses (\$800,000 ceiling per award)
- Increase the quantity and quality of food.
- Decrease the cost of high-quality foods.
- Promote healthy diets and good nutritional habits.
- Provide a weatherproof way of producing food.
- Foster business creation through produce sales.
- Promote regenerative agriculture.
- Microgrids (\$1,000,000 ceiling per award)
- Increase energy reliability while reducing costs.
- Boost tribal and Native community resilience.
- Promote economic growth.
- Underwrite tribal energy independence.
- Provide continuity of energy services in the event of a disaster or disruption.
- Welders to Elders (\$500,000 ceiling per award)
- Promote job growth.

- Promote personal and professional growth.
- Disrupt negative cycles linked to high unemployment.
- Provide individuals with a sense of purpose and direction.
- Build community resilience.
- Tradition in Action—A Native Elder Program (\$500,000 ceiling per award)
- Boost academic and cultural education.
- Support intergenerational knowledge transfer and cultural rootedness.
- Increase more productive and invested community members.
- Establish additional community-centered activities for elders.
- Establish long-horizon leadership pipelines.
- Indigenous Designs to Empower and Advance Self-Determination (IDEAS) (\$900,000 ceiling per award)
- Native communities will design projects that identify their community's most pressing needs and the proposed responses.

Applicants may apply for this award even if they have an active ANA award for SEDS or SEDS-AK.

ANA intends to fully fund the FY 2026 AI³ Action Institute at \$3,500,000 (ceiling).

B. ANA intends to fund one FY 2026 NCNTTA cooperative agreement with incremental funding for a 36-month project period with three 12-month budget periods. The total funding for the NCNTTA cooperative agreement is \$3,100,000 (ceiling).

2. Changes to Required Application Requirements

A. The following PAs will be included in the NOFO: PA 1: Seventh Generation Greenhouses; PA 2: Microgrids; PA 3: Welders to Elders; PA 4: Tradition in Action—A Native Elder Program; and PA 5: Indigenous Designs to Empower and Advance Self-Determination. Applicants will be required to include information on how they plan to sustain the project after the federal funding ends.

B. The NCNTTA cooperative agreement will focus on three capacity building service pillars. The first pillar will provide Comprehensive Capacity Building Services, which includes sharing resources and developing tools to strengthen organizational and programmatic capacity and support sustainability. The second pillar is Focused Capacity Building Services, which will promote knowledge sharing and build networks among ANA award recipients and their partners. The third pillar is Customized Capacity Building Services, which will provide tailored TTA through customized plans.

Applications will be accepted from both for-profit and non-profit entities that satisfy the eligibility criteria set forth in the TTA NOFO.

Statutory Authority: Sections 803, 804, and 814 of NAPA, as amended (42 U.S.C. 2991b, 2991c, 2992b–1).

Hope MacDonald Lone Tree,

Deputy Commissioner, Administration for Native Americans, Administration for Children and Families.

[FR Doc. 2026–05484 Filed 3–19–26; 8:45 am]

BILLING CODE 4184–34–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing opportunity should be directed to: David Yang at 240–695–6406, or *David.Yang@niaid.nih.gov*. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Gene Editing for ALPK1 p.Thr237Met

Description of Technology: ROSAH syndrome is a rare genetic disease caused by a mutation in the human alpha kinase 1 (ALPK1) gene (p.Thr237Met), leading to vision loss, swollen optic nerves, dry mouth, enlarged spleen, and frequent headaches. Researchers in the

Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach that can precisely fix the ALPK1 mutation without causing unwanted changes in the patient's DNA. This method uses a base editor combined with a guide RNA to safely and efficiently convert the pathogenic thymine of the mutation back to cytosine. In laboratory tests, this gene editing technology successfully repaired the mutation in patient-derived affected cells with high accuracy and no side effects.

This therapy could be delivered directly to the eye or salivary glands, or patient cells could be corrected outside the body and then returned to the patient, offering hope for personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

- Personalized therapy for individuals with disease secondary to the ALPK1 p.Thr237Met genetic variant.

Competitive Advantages:

- Highly accurate tool that directly repairs the faulty gene that causes ROSAH syndrome, while avoiding unwanted changes elsewhere in DNA.
- Corrects the mutation in most patient cells with few or no mistakes.
- Can be delivered directly to affected areas (e.g., eye or salivary glands) or can treat patient cells outside the body.
- Custom therapy for people with the ALPK1 mutation.
- Effective in cells that don't divide, unlike older gene editing methods.

Development Stage:

- Pre-Clinical.

Inventors: Dr. Christina Torres Kozycki, Dr. Colin L. Sweeney, Dr. Uimook Choi, all of NIAID.

Intellectual Property: HHS Reference No. E–044–2024–0. Provisional Patent Application No. 63/733,836, filed on December 13, 2024, and PCT Patent Application No. PCT/US2025/059432, filed on December 12, 2025.

Licensing Contact: To license this technology, please contact David Yang at 240–695–6406, or *David.Yang@niaid.nih.gov*, and reference E–044–2024–0.

Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to

further develop, evaluate, or commercialize this technology. Area of specific interest includes human clinical trials. For collaboration opportunities, please contact David Yang at 240–695–6406, or *David.Yang@niaid.nih.gov*.

Dated: March 18, 2026.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2026–05527 Filed 3–19–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Contracts: Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences.

Date: April 16, 2026.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate contract proposals.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Leroy Worth, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, Keystone Building 3082, Research Triangle Park, NC 27709, 984–287–3340, *worth@niehs.nih.gov*.

Name of Committee: Applied Immunology and Disease Control Integrated Review Group; Transmission of Vector-Borne and Zoonotic Diseases Study Section.

Date: April 16, 2026.

Time: 10:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.